TransMedics Group (NASDAQ:TMDX) Reaches New 52-Week High at $152.31

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price reached a new 52-week high on Friday . The stock traded as high as $152.31 and last traded at $148.57, with a volume of 87612 shares trading hands. The stock had previously closed at $147.82.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TMDX. Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price for the company. JPMorgan Chase & Co. increased their price target on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. TD Cowen increased their price objective on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Stephens assumed coverage on TransMedics Group in a research report on Tuesday, June 4th. They issued an “overweight” rating and a $151.00 price objective for the company. Finally, Oppenheimer increased their price objective on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.88.

TransMedics Group Trading Up 1.9 %

The company has a market cap of $4.96 billion, a PE ratio of -443.00 and a beta of 1.95. The business has a 50 day simple moving average of $131.01 and a two-hundred day simple moving average of $99.42. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) EPS. On average, analysts forecast that TransMedics Group, Inc. will post 0.77 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,744,059.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,744,059.55. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director David Weill sold 1,193 shares of TransMedics Group stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total transaction of $168,988.45. Following the transaction, the director now owns 10,732 shares in the company, valued at $1,520,187.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 290,501 shares of company stock worth $33,268,189. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in TransMedics Group by 2.5% in the third quarter. Rhumbline Advisers now owns 46,595 shares of the company’s stock valued at $2,551,000 after purchasing an additional 1,123 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in TransMedics Group during the third quarter worth about $203,000. Envestnet Asset Management Inc. increased its holdings in TransMedics Group by 104.0% in the 3rd quarter. Envestnet Asset Management Inc. now owns 80,752 shares of the company’s stock valued at $4,421,000 after buying an additional 41,168 shares during the period. Hsbc Holdings PLC bought a new position in TransMedics Group in the 3rd quarter valued at about $1,916,000. Finally, Qube Research & Technologies Ltd grew its holdings in shares of TransMedics Group by 31.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after purchasing an additional 20,081 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.